New filler study shows smoother smile lines with minimal risk
NCT ID NCT05235126
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested Decoria intense, a hyaluronic acid filler already on the market, to confirm it safely reduces nasolabial folds (smile lines). About 80 adults with at least moderate wrinkles received the filler, with an optional touch-up. Researchers measured wrinkle severity and tracked side effects over 12 months. The goal was to meet new EU safety rules and confirm the filler works as intended.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
94 people
The number who actually took part.
- Started
-
Feb 2022
- Finished
-
Mar 2023
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or Female, ≥18 years of age, of all weight spans, desiring correction of their nasolabial folds. 2. The subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the Informed Consent Form (ICF). 3. The subject has nasolabial folds considered at least moderate (grade 3) according to the Wrinkle Severity Rating Scale (WSRS), as assessed by the Principal Investigator. Exclusion Criteria: 1. Pregnant or lactating females. 2. Any previous hypersensitivity reaction to any constituent of the Investigational medical device (IMD) or to local anaesthetic products. 3. Any acute or chronic skin disease or inflammation (such as pimples, rashes or hives) within or close to the area selected for correction. 4. Any bleeding disorder or treatment with thrombolytics or anticoagulants. 5. Any treatment with interferon and ribavirin. 6. Any vaccine taken within 2 weeks prior to the treatment visit. 7. Any other intradermal injection, such as fillers or toxins, received in the same injection area within 6 months of the Screening and Treatment visit (Visit 1). 8. Participation in a clinical investigation study that may affect the safety or performance of this investigation, within one year of enrolment, or planned participation in such investigation at any time during this clinical investigation, as judged by the Principal Investigator. 9. Any other condition or treatment making the subject unsuitable for participation in the clinical investigation, as judged by the Principal Investigator. 10. Employees of the study site or the sponsor directly involved with the conduct of the investigation, or immediate family members of any such individuals.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Correction of nasolabial folds are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Florakliniken
Stockholm, Sweden
-
MyBeauty Clinic
Halmstad, 302 32, Sweden